NCT06985498View on ClinicalTrials.gov

CD22/CD19 CAR-T and Blinatumomab Combined With Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2026

Primary Completion Date

June 1, 2029

Study Completion Date

September 1, 2029

Conditions
Acute Lymphobkastic Leukemia
Interventions
COMBINATION_PRODUCT

Sandwich stratergy

The patients received blinatumoab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed after blinatumomab. Auto-HSCT was proceeded after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after stem cell reinfusion.

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER